201 related articles for article (PubMed ID: 25217221)
1. Is it cost-effective to use a test to decide which individuals with an intermediate cardiovascular disease risk would benefit from statin treatment?
Burgers LT; Nauta ST; Deckers JW; Severens JL; Redekop WK
Int J Cardiol; 2014 Oct; 176(3):980-7. PubMed ID: 25217221
[TBL] [Abstract][Full Text] [Related]
2. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy.
Lee KK; Cipriano LE; Owens DK; Go AS; Hlatky MA
Circulation; 2010 Oct; 122(15):1478-87. PubMed ID: 20876434
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.
de Vries FM; Denig P; Visser ST; Hak E; Postma MJ
Value Health; 2014 Mar; 17(2):223-30. PubMed ID: 24636380
[TBL] [Abstract][Full Text] [Related]
5. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
6. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
Greving JP; Visseren FL; de Wit GA; Algra A
BMJ; 2011 Mar; 342():d1672. PubMed ID: 21450800
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
[TBL] [Abstract][Full Text] [Related]
9. Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis.
Shiffman D; Arellano AR; Caulfield MP; Louie JZ; Bare LA; Devlin JJ; Melander O
BMC Cardiovasc Disord; 2016 Dec; 16(1):251. PubMed ID: 27927162
[TBL] [Abstract][Full Text] [Related]
10. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
11. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis.
Jarmul J; Pletcher MJ; Hassmiller Lich K; Wheeler SB; Weinberger M; Avery CL; Jonas DE; Earnshaw S; Pignone M
Circ Cardiovasc Qual Outcomes; 2018 Apr; 11(4):e004171. PubMed ID: 29650716
[TBL] [Abstract][Full Text] [Related]
13. Costs and health effects of adding functional foods containing phytosterols/-stanols to statin therapy in the prevention of cardiovascular disease.
Eussen SR; Feenstra TL; Toxopeus IB; Hoekstra J; Klungel OH; Verhagen H; van Kranen HJ; Rompelberg CJ
Eur J Pharmacol; 2011 Sep; 668 Suppl 1():S91-100. PubMed ID: 21816151
[TBL] [Abstract][Full Text] [Related]
14. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.
Blake GJ; Ridker PM; Kuntz KM
Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581
[TBL] [Abstract][Full Text] [Related]
15. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
16. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of optimizing use of statins in Australia: using outpatient data from the REACH Registry.
Ademi Z; Reid CM; Hollingsworth B; Stoelwinder J; Steg PG; Bhatt DL; Vale M; Liew D;
Clin Ther; 2011 Oct; 33(10):1456-65. PubMed ID: 21982384
[TBL] [Abstract][Full Text] [Related]
18. Population health impact of statin treatment in Canada.
Hennessy DA; Tanuseputro P; Tuna M; Bennett C; Perez R; Shields M; Ko DT; Tu J; Manuel DG
Health Rep; 2016 Jan; 27(1):20-8. PubMed ID: 26788719
[TBL] [Abstract][Full Text] [Related]
19. Combining population health and baseline risk strategy by determining an age cutoff for initiating statins in patients with diabetes: a population-based study.
Siyambalapitiya S; Bulugahapitiya U; Sithole J; Song S; Fernando DJ; Idris I
Diabetes Care; 2007 Aug; 30(8):2025-9. PubMed ID: 17519429
[TBL] [Abstract][Full Text] [Related]
20. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
